Mark Sculpher

Names

Identifer

Contact

Affiliations

Research profile

author of:

• Country-level cost-effectiveness thresholds: initial estimates and the need for further research (RePEc:chy:respap:109cherp)
  by Beth Woods & Paul Revill & Mark Sculpher & Karl Claxton
• Supporting the development of an essential health package: principles and initial assessment for Malawi (RePEc:chy:respap:136cherp)
  by Jessica Ochalek & Karl Claxton & Paul Revill & Mark Sculpher & Alexandra Rollinger
• Scoping review on social care economic evaluation methods (RePEc:chy:respap:150cherp)
  by Helen Weatherly & Rita Faria & Bernard Van den Berg & Mark Sculpher & Peter O’Neill & Kay Nolan & Julie Glanville & Jaana Isojarvi & Erin Baragula & Mary Edwards
• Economic analysis for health benefits package design (RePEc:chy:respap:165cherp)
  by James Love-Koh & Susan Griffin & Edward Kataika & Paul Revill & Sibusiso Sibandze & Simon Walker & Jessica Ochalek & Mark Sculpher & Matthias Arnold
• A critical structured review of economic evaluations of interventions for the prevention and treatment of osteoporosis (RePEc:chy:respap:169chedp)
  by Mark Sculpher & David Torgerson & Ron Goeree & Bernie O'Brien
• Improving the efficiency and relevance of health technology assessent: the role of iterative decision analytic modelling (RePEc:chy:respap:179chedp)
  by Elizabeth Fenwick & Karl Claxton & Mark Sculpher & Andrew Briggs
• Comparing smoking cessation to screening and brief intervention for alcohol in distributional cost effectiveness analysis to explore the sensitivity of results to socioeconomic inequalities characteri (RePEc:chy:respap:184cherp)
  by Fan Yang & Colin Angus & Ana Duarte & Duncan Gillespie & Mark Sculpher & Simon Walker & Susan Griffin
• Mark versus Luke? Appropriate Methods for the Evaluation of Public Health Interventions (RePEc:chy:respap:31cherp)
  by Karl Claxton & Mark Sculpher & Tony Culyer
• MRC-NICE scoping project: identifying the national institute for health and clinical excellence’s methodological research priorities and an initial set of priorities (RePEc:chy:respap:51cherp)
  by Louise Longworth & Laura Bojke & Jonathan Tosh & Mark Sculpher
• Appropriate Perspectives for Health Care Decisions (RePEc:chy:respap:54cherp)
  by Karl Claxton & Simon Walker & Steven Palmer & Mark Sculpher
• The value of implementation and the value of information: combined and uneven development (RePEc:chy:respap:5cherp)
  by Elisabeth Fenwick & Karl Claxton & Mark Sculpher
• Value-based pricing for pharmaceuticals: Its role, specification and prospects in a newly devolved NHS (RePEc:chy:respap:60cherp)
  by Karl Claxton & Mark Sculpher & Stuart Carroll
• Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions (RePEc:chy:respap:77cherp)
  by Simon Walker & Mark Sculpher & Karl Claxton & Steve Palmer
• Methods for the estimation of the NICE cost effectiveness threshold (RePEc:chy:respap:81cherp)
  by Karl Claxton & Steve Martin & Marta Soares & Nigel Rice & Eldon Spackman & Sebastian Hinde & Nancy Devlin & Peter C Smith & Mark Sculpher
• Using cost-effectiveness thresholds to determine value for money in low- and middle-income country healthcare systems: Are current international norms fit for purpose? (RePEc:chy:respap:98cherp)
  by Paul Revill & Simon Walker & Jason Madan & Andrea Ciaranello & Takondwa Mwase & Diana M Gibb & Karl Claxton & Mark J Sculpher
• Defining and characterising structural uncertainty in decision analytic models (RePEc:chy:respap:9cherp)
  by Laura Bojke & Karl Claxton & Stephen Palmer & Mark Sculpher
• We need to talk about values: a proposed framework for the articulation of normative reasoning in health technology assessment (RePEc:cup:hecopl:v:19:y:2024:i:2:p:153-173_2)
  by Charlton, Victoria & DiStefano, Michael & Mitchell, Polly & Morrell, Liz & Rand, Leah & Badano, Gabriele & Baker, Rachel & Calnan, Michael & Chalkidou, Kalipso & Culyer, Anthony & Howdon, Daniel & Hug
• Methods for assessing the cost-effectiveness of public health interventions: Key challenges and recommendations (RePEc:eee:hepoli:v:93:y:2009:i:2-3:p:85-92)
  by Weatherly, Helen & Drummond, Michael & Claxton, Karl & Cookson, Richard & Ferguson, Brian & Godfrey, Christine & Rice, Nigel & Sculpher, Mark & Sowden, Amanda
• Shared treatment decision making in a collectively funded health care system: possible conflicts and some potential solutions (RePEc:eee:socmed:v:54:y:2002:i:9:p:1369-1377)
  by Sculpher, Mark & Gafni, Amiram & Watt, Ian
• Striving for a societal perspective: a framework for economic evaluations when costs and effects fall on multiple sectors and decision-makers (RePEc:ehl:lserod:100541)
  by Walker, S. & Griffin, Susan & Asaria, Miqdad & Tsuchyia, Aki & Sculpher, Mark
• Using electronic health records to predict costs and outcomes in stable coronary artery disease (RePEc:ehl:lserod:101257)
  by Asaria, Miqdad & Walker, Simon & Palmer, Stephen & Gale, Chris P & Shah, Anoop D & Abrams, Keith R & Crowther, Michael & Manca, Andrea & Timmis, Adam & Hemingway, Harry & Sculpher, Mark
• Decision-making with Uncertainty: The Value of Information (RePEc:elg:eechap:14021_51)
  by Karl Claxton & Elisabeth Fenwick & Mark J. Sculpher
• Decision-making with Uncertainty: The Value of Information (RePEc:elg:eechap:3572_48)
  by Karl Claxton & Elizabeth Fenwick & Mark J. Sculpher
• Recognizing Preference Diversity: The Use of Preference Sub-Groups in Cost-Effectiveness Analysis (RePEc:hpa:wpaper:199901)
  by M Sculpher & A Gafni
• Income Effects of Reduced Health and Health Effects of Reduced Income: Implications for Health State Valuation (RePEc:hpa:wpaper:199902)
  by M Sculpher & B O'Brien
• Building Uncertainty into Cost-Effectiveness Rankings: Portfolio Risk-Return Trade-Offs and Implications for Decision Rules (RePEc:hpa:wpaper:199905)
  by B O'Brien & M Sculpher
• Understanding Harris’ understanding of CEA: is cost effective resource allocation undone? (RePEc:lee:wpaper:1005)
  by Richard Edlin & Christopher McCabe & Jeff Round & Judy Wright & Karl Claxton & Mark Sculpher & Richard Cookson
• Productivity Costs: Principles and Practice in Economic Evaluation (RePEc:ohe:monogr:000464)
  by Clive Pritchard;Martin Sculpher
• Decision Modelling for Health Economic Evaluation (RePEc:oxp:obooks:9780198526629)
  by Briggs, Andrew & Sculpher, Mark & Claxton, Karl
• Estimating the global demand curve for a leishmaniasis vaccine: A generalisable approach based on global burden of disease estimates (RePEc:plo:pntd00:0010471)
  by Sakshi Mohan & Paul Revill & Stefano Malvolti & Melissa Malhame & Mark Sculpher & Paul M Kaye
• Cost-Effectiveness Analysis of Acupuncture, Counselling and Usual Care in Treating Patients with Depression: The Results of the ACUDep Trial (RePEc:plo:pone00:0113726)
  by Eldon Spackman & Stewart Richmond & Mark Sculpher & Martin Bland & Stephen Brealey & Rhian Gabe & Ann Hopton & Ada Keding & Harriet Lansdown & Sara Perren & David Torgerson & Ian Watt & Hugh MacPherso
• Cost-effectiveness of adjunct non-pharmacological interventions for osteoarthritis of the knee (RePEc:plo:pone00:0172749)
  by Beth Woods & Andrea Manca & Helen Weatherly & Pedro Saramago & Eleftherios Sideris & Christina Giannopoulou & Stephen Rice & Mark Corbett & Andrew Vickers & Matthew Bowes & Hugh MacPherson & Mark Scul
• Reflecting the real value of health care resources in modelling and cost-effectiveness studies—The example of viral load informed differentiated care (RePEc:plo:pone00:0190283)
  by Paul Revill & Simon Walker & Valentina Cambiano & Andrew Phillips & Mark J Sculpher
• Adherence to the iDSI reference case among published cost-per-DALY averted studies (RePEc:plo:pone00:0205633)
  by Joanna Emerson & Ari Panzer & Joshua T Cohen & Kalipso Chalkidou & Yot Teerawattananon & Mark Sculpher & Thomas Wilkinson & Damian Walker & Peter J Neumann & David D Kim
• Health-related quality of life implications of plantar ulcers resulting from neuropathic damage caused by leprosy: An analysis from the trial of autologous blood products (TABLE trial) in Nepal (RePEc:plo:pone00:0315944)
  by Naomi Kate Gibbs & Jessica Ochalek & Indra Bahadur Napit & Dilip Shrestha & Pedro Saramago Goncalves & Richard J Lilford & Mark Sculpher
• Income Effects of Reduced Health and Health Effects of Reduced Income: (RePEc:sae:medema:v:20:y:2000:i:2:p:207-215)
  by Mark J. Sculpher & Bernie J. O'Brien
• Unfinished Symphony: A Tribute to the Life and Career of Bernie O’Brien (1959–2004) (RePEc:sae:medema:v:24:y:2004:i:5:p:538-544)
  by Andrew Briggs & Martin Buxton & Mike Drummond & Ron Goeree & Mark J. Sculpher & Andrew R. Willan
• Assessing the Cost-Effectiveness of New Pharmaceuticals in Epilepsy in Adults: The Results of a Probabilistic Decision Model (RePEc:sae:medema:v:25:y:2005:i:5:p:493-510)
  by Neil Hawkins & David Epstein & Michael Drummond & Jennifer Wilby & Anita Kainth & David Chadwick & Mark Sculpher
• Cost-Effectiveness Analysis of Treatments for Chronic Disease: Using R to Incorporate Time Dependency of Treatment Response (RePEc:sae:medema:v:25:y:2005:i:5:p:511-519)
  by Neil Hawkins & Mark Sculpher & David Epstein
• An Iterative Bayesian Approach to Health Technology Assessment: Application to a Policy of Preoperative Optimization for Patients Undergoing Major Elective Surgery (RePEc:sae:medema:v:26:y:2006:i:5:p:480-496)
  by Elisabeth Fenwick & Steve Palmer & Karl Claxton & Mark Sculpher & Keith Abrams & Alex Sutton
• Efficiency, Equity, and Budgetary Policies (RePEc:sae:medema:v:27:y:2007:i:2:p:128-137)
  by David M. Epstein & Zaid Chalabi & Karl Claxton & Mark Sculpher
• Cost-Effectiveness Analysis Using Data from Multinational Trials: The Use of Bivariate Hierarchical Modeling (RePEc:sae:medema:v:27:y:2007:i:4:p:471-490)
  by Andrea Manca & Paul C. Lambert & Mark Sculpher & Nigel Rice
• The Value of Implementation and the Value of Information: Combined and Uneven Development (RePEc:sae:medema:v:28:y:2008:i:1:p:21-32)
  by Elisabeth Fenwick & Karl Claxton & Mark Sculpher
• Identifying Research Priorities: The Value of Information Associated with Repeat Screening for Age-Related Macular Degeneration (RePEc:sae:medema:v:28:y:2008:i:1:p:33-43)
  by Laura Bojke & Karl Claxton & Mark J. Sculpher & Stephen Palmer
• Catalogue of EQ-5D Scores for the United Kingdom (RePEc:sae:medema:v:31:y:2011:i:6:p:800-804)
  by Patrick W. Sullivan & Julia F. Slejko & Mark J. Sculpher & Vahram Ghushchyan
• Effect of Treatment Interruption and Intensification of Antiretroviral Therapy on Health-Related Quality of Life in Patients with Advanced HIV (RePEc:sae:medema:v:32:y:2012:i:1:p:70-82)
  by Vilija R. Joyce & Paul G. Barnett & Adam Chow & Ahmed M. Bayoumi & Susan C. Griffin & Huiying Sun & Mark Holodniy & Sheldon T. Brown & Tassos C. Kyriakides & D. William Cameron & Mike Youle & Mark Scu
• Model Parameter Estimation and Uncertainty Analysis (RePEc:sae:medema:v:32:y:2012:i:5:p:722-732)
  by Andrew H. Briggs & Milton C. Weinstein & Elisabeth A. L. Fenwick & Jonathan Karnon & Mark J. Sculpher & A. David Paltiel
• Methods Development for Health Technology Assessment (RePEc:sae:medema:v:33:y:2013:i:3:p:313-315)
  by Mark Sculpher
• The Value of Heterogeneity for Cost-Effectiveness Subgroup Analysis (RePEc:sae:medema:v:34:y:2014:i:8:p:951-964)
  by Manuel A. Espinoza & Andrea Manca & Karl Claxton & Mark J. Sculpher
• How to Invest in Getting Cost-effective Technologies into Practice? A Framework for Value of Implementation Analysis Applied to Novel Oral Anticoagulants (RePEc:sae:medema:v:37:y:2017:i:2:p:148-161)
  by Rita Faria & Simon Walker & Sophie Whyte & Simon Dixon & Stephen Palmer & Mark Sculpher
• Establishing the Value of Diagnostic and Prognostic Tests in Health Technology Assessment (RePEc:sae:medema:v:38:y:2018:i:4:p:495-508)
  by Marta O. Soares & Simon Walker & Stephen J. Palmer & Mark J. Sculpher
• Future Directions for Cost-effectiveness Analyses in Health and Medicine (RePEc:sae:medema:v:38:y:2018:i:7:p:767-777)
  by Peter J. Neumann & David D. Kim & Thomas A. Trikalinos & Mark J. Sculpher & Joshua A. Salomon & Lisa A. Prosser & Douglas K. Owens & David O. Meltzer & Karen M. Kuntz & Murray Krahn & David Feeny & An
• Health Opportunity Costs: Assessing the Implications of Uncertainty Using Elicitation Methods with Experts (RePEc:sae:medema:v:40:y:2020:i:4:p:448-459)
  by Marta O. Soares & Mark J. Sculpher & Karl Claxton
• Authors’ Response to: “Health Opportunity Costs and Expert Elicitation: A Comment on Soares et al.†by Sampson, Firth, and Towse (RePEc:sae:medema:v:41:y:2021:i:3:p:258-260)
  by Marta O. Soares & Mark J. Sculpher & Karl Claxton
• Program Evaluation of Population- and System-Level Policies: Evidence for Decision Making (RePEc:sae:medema:v:42:y:2022:i:1:p:17-27)
  by Simon Walker & Aimee Fox & James Altunkaya & Tim Colbourn & Mike Drummond & Susan Griffin & Nils Gutacker & Paul Revill & Mark Sculpher
• What is the Quality of Economic Evaluations of Non-Drug Therapies? A Systematic Review and Critical Appraisal of Economic Evaluations of Radiotherapy for Cancer (RePEc:spr:aphecp:v:12:y:2014:i:5:p:497-510)
  by M. Barbieri & H. Weatherly & R. Ara & H. Basarir & M. Sculpher & R. Adams & H. Ahmed & C. Coles & T. Guerrero-Urbano & C. Nutting & M. Powell
• Striving for a Societal Perspective: A Framework for Economic Evaluations When Costs and Effects Fall on Multiple Sectors and Decision Makers (RePEc:spr:aphecp:v:17:y:2019:i:5:d:10.1007_s40258-019-00481-8)
  by Simon Walker & Susan Griffin & Miqdad Asaria & Aki Tsuchiya & Mark Sculpher
• Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England (RePEc:spr:aphecp:v:23:y:2025:i:1:d:10.1007_s40258-024-00924-x)
  by Beth Woods & Ben Kearns & Laetitia Schmitt & Dina Jankovic & Claire Rothery & Sue Harnan & Jean Hamilton & Alison Scope & Shijie Ren & Laura Bojke & Mark Wilcox & William Hope & Colm Leonard & Philip
• An economic model for the prevention of MRSA infections after surgery: non-glycopeptide or glycopeptide antibiotic prophylaxis? (RePEc:spr:eujhec:v:11:y:2010:i:1:p:57-66)
  by Rachel Elliott & Helen Weatherly & Neil Hawkins & Gillian Cranny & Duncan Chambers & Lindsey Myers & Alison Eastwood & Mark Sculpher
• Estimating utility data from clinical indicators for patients with stable angina (RePEc:spr:eujhec:v:6:y:2005:i:4:p:347-353)
  by Louise Longworth & Martin Buxton & Mark Sculpher & David Smith
• Costs Incurred by Patients Undergoing Advanced Colorectal Cancer Therapy (RePEc:spr:pharme:v:17:y:2000:i:4:p:361-370)
  by Mark Sculpher & Michael Palmer & Anne Heyes
• Assessing Generalisability in Model-Based Economic Evaluation Studies (RePEc:spr:pharme:v:24:y:2006:i:12:p:1181-1197)
  by Hege Urdahl & Andrea Manca & Mark Sculpher
• A Comparison of the Cost Effectiveness of Pharmacotherapy or Surgery (Laparoscopic Fundoplication) in the Treatment of GORD (RePEc:spr:pharme:v:25:y:2007:i:10:p:829-841)
  by Laura Bojke & Edward Hornby & Mark Sculpher
• Recombinant Erythropoietin for Chemotherapy-Related Anaemia (RePEc:spr:pharme:v:25:y:2007:i:3:p:223-237)
  by Diego Ossa & Andrew Briggs & Emma McIntosh & Warren Cowell & Tim Littlewood & Mark Sculpher
• Real Economics Needs to Reflect Real Decisions (RePEc:spr:pharme:v:30:y:2012:i:2:p:133-136)
  by Mark Sculpher & Karl Claxton
• Golimumab for the Treatment of Psoriatic Arthritis (RePEc:spr:pharme:v:30:y:2012:i:4:p:257-270)
  by Huiqin Yang & Dawn Craig & David Epstein & Laura Bojke & Kate Light & Ian Bruce & Mark Sculpher & Nerys Woolacott
• Acknowledging Patient Heterogeneity in Economic Evaluation (RePEc:spr:pharme:v:31:y:2013:i:2:p:111-123)
  by Janneke Grutters & Mark Sculpher & Andrew Briggs & Johan Severens & Math Candel & James Stahl & Dirk Ruysscher & Albert Boer & Bram Ramaekers & Manuela Joore
• Should the Lambda (λ) Remain Silent? (RePEc:spr:pharme:v:34:y:2016:i:4:d:10.1007_s40273-015-0359-7)
  by Hossein Haji Ali Afzali & Jonathan Karnon & Mark Sculpher
• After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator? (RePEc:spr:pharme:v:38:y:2020:i:3:d:10.1007_s40273-019-00882-6)
  by Mark Sculpher & Stephen Palmer
• Jointly Modelling Economics and Epidemiology to Support Public Policy Decisions for the COVID-19 Response: A Review of UK Studies (RePEc:spr:pharme:v:39:y:2021:i:8:d:10.1007_s40273-021-01045-2)
  by Ana Duarte & Simon Walker & Andrew Metry & Ruth Wong & Jasmina Panovska-Griffiths & Mark Sculpher
• Developing the EQ-5D-5L Value Set for Uganda Using the ‘Lite’ Protocol (RePEc:spr:pharme:v:40:y:2022:i:3:d:10.1007_s40273-021-01101-x)
  by Fan Yang & Kenneth R. Katumba & Bram Roudijk & Zhihao Yang & Paul Revill & Susan Griffin & Perez N. Ochanda & Mohammed Lamorde & Giulia Greco & Janet Seeley & Mark Sculpher
• Using Age-Specific Values for Pediatric HRQoL in Cost-Effectiveness Analysis: Is There a Problem to Be Solved? If So, How? (RePEc:spr:pharme:v:41:y:2023:i:10:d:10.1007_s40273-023-01300-8)
  by Nancy J. Devlin & Tianxin Pan & Mark Sculpher & Mark Jit & Elly Stolk & Donna Rowen & Barend Hout & Richard Norman
• A Framework for Using Cost-effectiveness Analysis to Support Pricing and Reimbursement Decisions for New Pharmaceuticals in a Context of Evolving Treatments, Prices, and Evidence (RePEc:spr:pharme:v:43:y:2025:i:4:d:10.1007_s40273-024-01450-3)
  by Beth Woods & Alfredo Palacios & Mark Sculpher
• Recognizing diversity in public preferences: The use of preference sub‐groups in cost‐effectiveness analysis (RePEc:wly:hlthec:v:10:y:2001:i:4:p:317-324)
  by Mark Sculpher & Amiram Gafni
• Representing uncertainty: the role of cost‐effectiveness acceptability curves (RePEc:wly:hlthec:v:10:y:2001:i:8:p:779-787)
  by Elisabeth Fenwick & Karl Claxton & Mark Sculpher
• Recognising diversity in public preferences: the use of preference sub‐groups in cost‐effectiveness analysis. Authors' reply (RePEc:wly:hlthec:v:11:y:2002:i:7:p:653-654)
  by Mark Sculpher & Amiram Gafni
• Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra (RePEc:wly:hlthec:v:14:y:2005:i:4:p:339-347)
  by Karl Claxton & Mark Sculpher & Chris McCabe & Andrew Briggs & Ron Akehurst & Martin Buxton & John Brazier & Tony O'Hagan
• Assessing generalisability by location in trial‐based cost‐effectiveness analysis: the use of multilevel models (RePEc:wly:hlthec:v:14:y:2005:i:5:p:471-485)
  by Andrea Manca & Nigel Rice & Mark J. Sculpher & Andrew H. Briggs
• Estimating mean QALYs in trial‐based cost‐effectiveness analysis: the importance of controlling for baseline utility (RePEc:wly:hlthec:v:14:y:2005:i:5:p:487-496)
  by Andrea Manca & Neil Hawkins & Mark J. Sculpher
• Discounting and cost‐effectiveness in NICE – stepping back to sort out a confusion (RePEc:wly:hlthec:v:15:y:2006:i:1:p:1-4)
  by Karl Claxton & Mark Sculpher & Anthony Culyer & Chris McCabe & Andrew Briggs & Ron Akehurst & Martin Buxton & John Brazier
• Evidence synthesis, parameter correlation and probabilistic sensitivity analysis (RePEc:wly:hlthec:v:15:y:2006:i:4:p:373-381)
  by A. E. Ades & Karl Claxton & Mark Sculpher
• Whither trial‐based economic evaluation for health care decision making? (RePEc:wly:hlthec:v:15:y:2006:i:7:p:677-687)
  by Mark J. Sculpher & Karl Claxton & Mike Drummond & Chris McCabe
• Sins of omission and obfuscation: IQWIG's guidelines on economic evaluation methods (RePEc:wly:hlthec:v:19:y:2010:i:10:p:1132-1136)
  by Mark Sculpher & Karl Claxton
• Dangerous omissions: the consequences of ignoring decision uncertainty (RePEc:wly:hlthec:v:20:y:2011:i:2:p:212-224)
  by Susan C. Griffin & Karl P. Claxton & Stephen J. Palmer & Mark J. Sculpher
• Causes For Concern: Is Nice Failing To Uphold Its Responsibilities To All Nhs Patients? (RePEc:wly:hlthec:v:24:y:2015:i:1:p:1-7)
  by Karl Claxton & Mark Sculpher & Stephen Palmer & Anthony J Culyer
• Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs (RePEc:wly:hlthec:v:26:y:2017:i:s1:p:109-123)
  by Claire Rothery & Karl Claxton & Stephen Palmer & David Epstein & Rosanna Tarricone & Mark Sculpher
• Social value and individual choice: The value of a choice‐based decision‐making process in a collectively funded health system (RePEc:wly:hlthec:v:27:y:2018:i:2:p:e28-e40)
  by Manuel Antonio Espinoza & Andrea Manca & Karl Claxton & Mark Sculpher
• How to design the cost‐effectiveness appraisal process of new healthcare technologies to maximise population health: A conceptual framework (RePEc:wly:hlthec:v:27:y:2018:i:2:p:e41-e54)
  by Kasper M. Johannesen & Karl Claxton & Mark J. Sculpher & Allan J. Wailoo
• Distributional cost effectiveness analysis of West Yorkshire low emission zone policies (RePEc:wly:hlthec:v:29:y:2020:i:5:p:567-579)
  by Susan Griffin & Simon Walker & Mark Sculpher
• Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients served by health systems (RePEc:wly:hlthec:v:30:y:2021:i:11:p:2649-2666)
  by Beth Woods & Aimée Fox & Mark Sculpher & Karl Claxton
• Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments required (RePEc:wly:hlthec:v:33:y:2024:i:4:p:804-819)
  by Beth Woods & James Lomas & Mark Sculpher & Helen Weatherly & Karl Claxton
• Sensitivity analysis in economic evaluation: A review of published studies (RePEc:wly:hlthec:v:4:y:1995:i:5:p:355-371)
  by Andrew Briggs & Mark Sculpher
• The cost‐effectiveness of preference‐based treatment allocation: the case of hysterectomy versus endometrial resection in the treatment of menorrhagia (RePEc:wly:hlthec:v:7:y:1998:i:2:p:129-142)
  by Mark Sculpher
• Global Health Economics:Shaping Health Policy in Low- and Middle-Income Countries (RePEc:wsi:wsbook:11045)
  by None
• Cost-Effectiveness Thresholds: Guiding Health Care Spending for Population Health Improvement (RePEc:wsi:wschap:9789813272378_0003)
  by Paul Revill & Jessica Ochalek & James Lomas & Ryota Nakamura & Beth Woods & Alexandra Rollinger & Marc Suhrcke & Mark Sculpher & Karl Claxton & Peter Berman
• Supporting the Development of Health Benefits Packages (HBPs): Principles and Initial Assessment for Malawi (RePEc:wsi:wschap:9789813272378_0010)
  by Jessica Ochalek & Gerald Manthalu & Dominic Nkhoma & Finn McGuire & Alexandra Rollinger & Paul Revill & Mark Sculpher & Karl Claxton & Peter Berman
• Economic Evaluation in Health Care Research and Development: Undertake it Early and Often (RePEc:wuk:hergdp:0012)
  by Mark Sculpher & Michael Drummond & Martin Buxton
• Antenatal testing for HIV Infection: Developing a Model for Economic Evaluation (RePEc:wuk:hergdp:0014)
  by Andrew Briggs & Diana Gibb & Mark Sculpher & Sandra MacDonagh & Tony Ades